A controlled trial of anti-tuberculosis chemotherapy in the early complicated pneumoconiosis of coalworkers

J. D. BALL, G. BERRY, W. G. CLARKE, J. C. GILSON, AND J. THOMAS

with the assistance of

CATHERINE EXALL AND MARJORIE ROBERTS

From the Pneumoconiosis Research Unit, Llandough Hospital, Penarth, Glam.

A controlled trial in coalminers under the age of 50 in South Wales with sputum-negative, early complicated pneumoconiosis was used to compare three regimes: (1) chemotherapy (rest in hospital and 1 g. streptomycin, 200 mg. INH, 10 g. PAS, for 3 months; then 200 mg. INH, 10 g. PAS for 9 months); (2) rest (in hospital for 3 months); and (3) a working group. The initial and three-year radiographs were assessed by two methods in 173 (96%) of the 180 men entering the trial. No beneficial effect of chemotherapy was demonstrated and this factor was not related to the completeness of the chemotherapy. The variation between individuals in the rate of progression and in the development of new shadows was unrelated to chest symptoms, smoking habits, initial erythrocyte sedimentation rate, or special features in the initial radiographs, so these did not provide any useful predictive characteristics. Those with an initial negative Mantoux (1 T.U.) showed significantly less progression than those with a positive Mantoux. The lack of benefit and the short- and long-term complications of chemotherapy (weight gain, reduction in ventilatory capacity, dyspepsia, and streptomycin toxicity) show that this treatment is contra-indicated in miners with early complicated pneumoconiosis without a positive sputum. That new shadows develop during chemotherapy adds to the evidence from other sources that tuberculosis is unlikely to be a major factor in the pathogenesis of complicated pneumoconiosis in this area. Mycobacterium peregrinum (Runyon group IV) was isolated in three cases.

Complicated pneumoconiosis is more common in South Wales coalfields than in other areas of Great Britain. Over 2,000 cases were recognized in South Wales in a population of 72,000 working miners during the periodic radiographic survey by the National Coal Board between 1959 and 1963 (National Coal Board, 1964). Cochrane (1962) showed that in the Rhondda Fach in South Wales the attack rate of complicated pneumoconiosis (progressive massive fibrosis—P.M.F.) was related to the category of simple pneumoconiosis, and that 1–2% of miners with simple pneumoconiosis may be expected to develop complicated pneumoconiosis each year. How to treat miners with early complicated pneumoconiosis is therefore an important problem, especially as it has been shown that this form of pneumoconiosis can cause moderate or severe disability and increased mortality (Gilson and Hugh-Jones, 1955; Cochrane and Higgins, 1961; Cochrane, Carpenter, Moore, and Thomas, 1964).

Anti-tuberculosis chemotherapy had been tried frequently in sputum-negative cases in our patients in hospital but was not found to be effective, though on account of the slow progression seen in most cases of P.M.F. a beneficial long-term effect might have been undetected. Two previous controlled trials have been reported. Miall, Oldham, and Cochrane (1954) used isoniazid (100 mg. b.d. for two 3-month courses) shortly after its discovery. McCallum (1961) used isoniazid (200 mg. a day, PAS 10 g. a day for 12 months). Neither trial revealed any clear evidence of benefit, but the first trial used a regime not now regarded as adequate chemotherapy, and in the second trial a complete follow-up was not possible.
If a further trial was to be made, it was essential that the scientific, technical, and ethical aspects should be considered in detail. To do this a committee was convened by the Medical Research Council under Professor C. H. Stuart-Harris in 1958. The unanimous conclusion of the committee was that a further trial was desirable but 'grave doubts were expressed on the possibility of completing the trial successfully'. The trial differed from most anti-tuberculosis chemotherapy trials in important respects which made it unusually difficult: (1) By definition the cases admitted did not have tubercle bacilli in the sputum, so a valuable index of the effect of therapy was removed. (2) The lesion in P.M.F. progresses more slowly than does tuberculosis. (3) The fibrotic nature of the lesions made it probable that the trial would be one-sided in the sense that we should be able to detect only 'no change' or 'progression' and would not have the group of 'improvement' on which the results of most trials of drugs for tuberculosis are based radiologically. (4) Studies in the Rhondda (Cochrane and Carpenter, 1956) had produced some evidence that the progression of the disease might be linked with physical activity, so a test of this factor had to be included in the design of the trial.

**PLAN OF TRIAL**

The original plan was to follow up over a period of at least three years 225 working miners randomly allocated into the three groups shown in Table I.

**TABLE I**

<table>
<thead>
<tr>
<th>Period (months)</th>
<th>Group 1 'Chemotherapy'</th>
<th>Group 2 'Rest'</th>
<th>Group 3 'Working'</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>Hospital rest 1 g. Streptomycin 200 mg. INH 10 g. PAS daily</td>
<td>Hospital rest</td>
<td>Working</td>
</tr>
<tr>
<td>9</td>
<td>Working 200 mg. INH 10 g. PAS daily</td>
<td>Working</td>
<td>Working</td>
</tr>
<tr>
<td>24</td>
<td>Working No drugs</td>
<td>Working</td>
<td>Working</td>
</tr>
</tbody>
</table>

The group with hospital rest alone is unusual and was put in for the reasons mentioned, and because of the great importance of achieving an unambiguous result from a trial which might not be repeatable. At the time the trial was started, the results of the Madras study (Fox, 1962), showing the negligible benefit of hospital rest in tuberculosis, were not available. In selecting the chemotherapy we were forced to compromise between a regimen which was certainly adequate to control any active tuberculous focus and one which could and would be taken by a majority of miners when back at work. The addition of steroids was considered but rejected on account of the possible risk of complications and the absence of evidence of benefit in ward cases.

**CRITERIA FOR SELECTION** The subjects were working miners up to the age of 50, sputum-negative (6 or more negative cultures), and showing on the chest film opacities of a total diameter not exceeding 8 cm., thought by a majority of a panel of three to be examples of complicated pneumoconiosis of coal-workers. In miners fulfilling these criteria the only reason for exclusion was a history of previous treatment with anti-tuberculosis drugs or the presence of another condition sufficiently severe to make it improbable that the man would be able to continue his employment and be followed over a period of three years at least.

**POPULATION SELECTION** The trial started at the time of the first periodic survey by the National Coal Board. This ensured that working miners who came within the criteria for the trial could be recruited from the whole of the South Wales coalfield. The majority of men were recruited from this survey. A few came from those who applied for compensation to the Pneumoconiosis Medical Panels. The results are, therefore, likely to be applicable at least to the whole of the South Wales area.

The purpose of the trial was explained to the miners and the Union representatives at all levels. Only two-thirds of those asked by the doctors of the National Coal Board or the Pneumoconiosis Panels agreed to attend the Pneumoconiosis Research Unit for interview. Of those who attended, all but one who were suitable agreed to take part in the investigation. The trial remained open for three years and was closed after 180 out of the anticipated 225 had been enrolled. One of three treatment regimes was randomly selected within groups of six as the men attended for interview.

**COURSE OF TRIAL** At the initial interview a PA chest radiograph, answers to a questionnaire on chest symptoms, previous illnesses, and smoking habits, and industrial history were obtained. A full physical examination was made and specimens of blood, urine, and sputum were collected. The forced expiratory volume (FEV<sub>0.75</sub>) and forced vital capacity (FVC) were recorded (McKerrow, McDermott, and Gilson, 1960), and a Mantoux test was done. These procedures were repeated at 3, 12, 24, and 36 months.

One man developed a TB-positive sputum and was withdrawn from the trial. Three men gave intermittent positive cultures of anonymous mycobacteria but without clinical symptoms, so were retained in
A controlled trial of anti-tuberculosis chemotherapy in pneumoconiosis of coalworkers

The size of the three groups during the progress of the trial is shown in Table II. The sustained co-operation shown by these figures—96% were examined at 36 months and 94% regularly during the three years after admission to the trial—showed that the doubts of the committee were fortunately unfounded.

**TABLE II**  
**NUMBER OF SUBJECTS**

<table>
<thead>
<tr>
<th>Admissions</th>
<th>'Chemotherapy'</th>
<th>'Rest'</th>
<th>'Working'</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deaths</td>
<td>60</td>
<td>59</td>
<td>61</td>
<td>180</td>
</tr>
<tr>
<td>Lapses at 3 years</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>No. examined for progression at 3 years</td>
<td>10</td>
<td>0</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>No. examined regularly (i.e., 0, 3, 12, 24, 36 months)</td>
<td>58</td>
<td>57</td>
<td>58</td>
<td>173</td>
</tr>
</tbody>
</table>

The 'difference in the last two rows consists of semi-lapses, i.e., subjects who had lapsed during the trial but were persuaded to attend for a 3-year examination.

The three deaths were unrelated to treatment:
- I killed in accident underground;
- I died of coronary thrombosis;
- I died of _B. proteus_ septicaemia.

**COMPARABILITY OF THE THREE GROUPS** Table III shows that the men in the three groups on entry did not differ significantly in age, years of underground work, weight, height, or ventilatory capacity. The average normal value of FEV₁₀ for men aged 44 and entry into the trial. All films were inspected for technique by W. G. C. and J. D. B. or J. C. G. before the man left on each visit.

Assessment of the films for change in the extent of the shadows was made in two ways: visual comparison by two observers independently; and a measurement of the area of the shadows. In the first method, two of the authors (J. D. B. and J. C. G.), with knowledge of the serial order of the films but no knowledge of the treatment groups, assessed changes in the original shadows ('progression' or 'regression') or the development of new shadows at least 1 cm.² in area ('attack'). Changes from the original shadows were read as definite progression (P), doubtful progression (?>P), no change (NC), doubtful regression (?>R), and definite regression (R). In the second method the same two observers traced the outline of the shadows on to transparent plastic sheets without knowing the group or the order of the films. The areas of the shadows were then measured, using squared paper, by a third observer. In this way we hoped to get as much unbiased information from the films as possible.

**RESULTS**

**VISUAL COMPARISON OF RADIOGRAPHs** The comparison of the films just before treatment and at approximately 36 months¹ is shown in Tables IV

**TABLE III**  
**COMPARISON OF GROUPS AT ENTRY**

<table>
<thead>
<tr>
<th>No. (excluding lapses and deaths)</th>
<th>'Chemotherapy'</th>
<th>'Rest'</th>
<th>'Working'</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Mean</td>
<td>58</td>
<td>57</td>
</tr>
<tr>
<td>Range</td>
<td>(36-50)</td>
<td>44-1</td>
<td>43-7</td>
</tr>
<tr>
<td>Years</td>
<td>Mean</td>
<td>27-9</td>
<td>26-9</td>
</tr>
<tr>
<td>S.D.</td>
<td>(5-9)</td>
<td>(6-1)</td>
<td>(5-5)</td>
</tr>
<tr>
<td>Weight (kg.)</td>
<td>Mean</td>
<td>68-6</td>
<td>69-4</td>
</tr>
<tr>
<td>S.D.</td>
<td>(7-6)</td>
<td>(10-0)</td>
<td>(10-8)</td>
</tr>
<tr>
<td>Height (cm.)</td>
<td>Mean</td>
<td>167</td>
<td>168</td>
</tr>
<tr>
<td>S.D.</td>
<td>(5-3)</td>
<td>(6-2)</td>
<td>(6-9)</td>
</tr>
<tr>
<td>FEV₁₀ (l.)</td>
<td>Mean</td>
<td>2-72</td>
<td>2-71</td>
</tr>
<tr>
<td>S.D.</td>
<td>(0-51)</td>
<td>(0-47)</td>
<td>(0-49)</td>
</tr>
</tbody>
</table>

168 cm. in height is 3-3 l. (Cotes, Rossiter, Higgins, and Gilson, 1966). This corresponds to an FEV₁₀ of 2-95 l. (McKerrow, McDermott, and Gilson, 1960). Thus the average figure of 2-71 l. (Table III) is only slightly below normal, confirming the view that early P.M.F. has little influence on ventilatory capacity (Cochrane and Higgins, 1961).

**METHODS OF ASSESSMENT** We relied principally on chest radiographs for assessing the effect of treatment. Special care was taken to see that each new film was technically indistinguishable from the man's film on

1In all three cases the organism isolated was _M. pergerdeum_, a rapidly growing bacillus belonging to _Rumyantsev_ group IV. This has been isolated frequently in South Wales and on present evidence does not appear to be pathogenic (Marks, 1968).

1The films were taken between 32 and 42 months in all except seven cases; in these, the final film was taken at 24, 28, 43, 44 (×3), and 57 months.
tendency to record smaller differences which were ignored by X.

In Table V the only notable difference between the treatment groups is that observer X assessed more cases as 'no change' in the 'rest' group than in the other two groups, but this difference was not significant at the 5% level (P=0.07). The Table shows that the difference is due to fewer cases of 'doubtful progression' in the 'rest' group and not to a reduction in the number of 'definite progressions'.

**TABLE V**

<table>
<thead>
<tr>
<th>GROUP</th>
<th>P</th>
<th>?P</th>
<th>NC</th>
<th>R and R</th>
<th>Total</th>
<th>Attacks and ? Attacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy Rest Working</td>
<td>17(3)</td>
<td>12(2)</td>
<td>27(3)</td>
<td>4</td>
<td>58</td>
<td>7</td>
</tr>
<tr>
<td>Chemotherapy Rest Working</td>
<td>18(4)</td>
<td>17(3)</td>
<td>19(3)</td>
<td>26(1)</td>
<td>58</td>
<td>8</td>
</tr>
<tr>
<td>Chemotherapy Rest Working</td>
<td>13(3)</td>
<td>12(2)</td>
<td>31(1)</td>
<td>0</td>
<td>58</td>
<td>5</td>
</tr>
<tr>
<td>Chemotherapy Rest Working</td>
<td>8(6)</td>
<td>6(3)</td>
<td>42(9)</td>
<td>1</td>
<td>57</td>
<td>3</td>
</tr>
<tr>
<td>Chemotherapy Rest Working</td>
<td>16(3)</td>
<td>15(3)</td>
<td>35(9)</td>
<td>1</td>
<td>58</td>
<td>3</td>
</tr>
<tr>
<td>Chemotherapy Rest Working</td>
<td>13(2)</td>
<td>10(2)</td>
<td>26(0)</td>
<td>1</td>
<td>57</td>
<td>2</td>
</tr>
</tbody>
</table>

(Distribution of Attacks and ? Attacks given above numbers)

Table V also shows the numbers of 'attacks' read by each observer; these show no significant relation to treatment. Observer Y again read more abnormality than X. If those cases read as 'no change' and 'attack' are excluded from the 'no change' category, the conclusions are not qualitatively altered.

The mean incidence of the two observers for progressions and attacks in the three groups is shown in Figure 1. Although the 'working' group showed somewhat greater progression, this difference does not approach statistical significance.

**SHADOW AREAS** The outlines of the shadows were traced on to transparent plastic sheets for 171 subjects by both observers and the areas drawn were measured for the 0 and 36-month films. Observer Y tended to draw smaller areas than observer X, the mean difference being 1.2 cm². The initial and 36-month areas (means of the two observers) are shown for each group in Figure 2. The initial areas of the shadows varied from 2 to 35 cm², but the group differences in the initial values were not significant when compared with the variation between men within the treatment groups.

To assess the group differences during the trial the change in area of the shadows between the initial and 3-year films was calculated (making a proportional adjustment when the interval was not exactly 36 months).

The agreement between observers, ignoring consistent differences between them, gives an indication of the accuracy of a value meaned over the two observers. For initial area the observer error led to a standard deviation of 3.4 cm² and for change in area the corresponding figure was 1.9 cm². These values are 25% and 170% of the corresponding mean values and thus the effect of observer disagreement is relatively most marked for the change in area. If the absolute value of the area was of prime interest it would be better to transform the areas to square roots to give a more symmetrical distribution within the population. For the difference between the two occasions, however, the transformation is not necessary and the effect of the differences between observers is
A controlled trial of anti-tuberculosis chemotherapy in pneumoconiosis of coalworkers

such that over 40% of the variation in increase in area (measured over observers) is due to observer 'error', the remaining variation being due to actual variation between men within treatment groups.

The mean increase found by observer X was 0.75 cm.² for the chemotherapy group and 1.0 cm.² for both the rest and working groups. For observer Y the differences were larger, the means being 0.6 cm.² for the chemotherapy group, 1.2 cm.² for the rest group, and 2.0 cm.² for the working group. Differences between the treatment groups were not significant for either observer. However, both observers found a few cases with a large increase in area which appear heterogeneous with the overall distribution of the areas of the shadows. These cases occurred only in the rest and working groups but their number is so small that little statistical significance can be attached to the observation. These cases have an appreciable influence on the means of the rest and working groups, particularly for observer Y but, even after excluding these possible non-representative cases, there is no significant effect of treatment.

Summarizing the two methods of assessment, the only significant treatment effect was that one observer found that the rest group showed least progression. This effect (P=0.07) was due to his recording fewer 'doubtful progressions' and more 'no changes', and was unsupported by the other observer. To accept the finding would imply that the chemotherapy had had a negative effect, a finding incompatible with any hypothesis yet advanced. It is, therefore, concluded that no treatment differences of any clinical importance are established by the trial.

It remains possible that within a group of non-responders, sub-groups of responders are present. Both observers found a few cases with a large area increase in the rest and working groups but not in the chemotherapy group. If such sub-groups of potential responders to chemotherapy do exist it has not been possible to identify them in this trial by any features in the initial films. An attempt to do this was made by Dr. C. B. McKerrow who examined the first films and classified them into four grades according to the sharpness of the outline of the P.M.F. shadows and the degree of variability in the size of small opacities. Lack of clarity in the outline of large shadows might denote a process of extension, while variability in the size of the small opacities might indicate an early stage in the development of new massive lesions. The classification included both these attributes simultaneously; although this classification appeared to select subjects with subsequent radiological progression, it did not do so sufficiently precisely to aid interpretation of the trial.

COMPLETENESS OF THERAPY Of the 59 patients allocated to chemotherapy who entered hospital, 49 took the full dose; two of the remainder took over 75% of the prescribed dose. We expected to meet difficulties during the nine months of treatment at home. A close watch on the completeness of treatment was made by weekly estimations of urine for isoniazid and fortnightly visits from our health visitor (C.E.). Eighty-six per cent of the weekly urine samples were obtained, and 89% were positive. Fifteen patients had less than 20 positive urine specimens in the nine months. Thirty-one of the patients took 90–100% of the prescribed dose, 15 took 70–90%, 9 took 50–70%, and 4 less than 50%, these figures being estimated by the number of cachets remaining. These precautions did not exclude the possibility that uncooperative patients may have destroyed some of the cachets, or taken them only for a day before sending in their urine if they guessed the purpose of this test.

A total of 12 patients probably took less than half their total chemotherapy. We examined the possibility that these patients formed a large proportion of those with progression on the radiographs, but this was not so. Removing these patients from the analysis did not alter the conclusions reached in the previous section.

DISADVANTAGES OF THERAPY

Streptomycin vertigo Vertigo was sufficiently marked to stop treatment in five cases after 29–57 g had been given, at between the fourth and eighth weeks. The vertigo disappeared within a few weeks in one subject, but continued to be slight or moderate in the dark, though negligible in daylight, for over three years in four men. A further nine cases had only slight vertigo and treatment was not stopped in these. The vertigo ceased within 2–8 weeks of completing the 3-months course in eight cases but was still noticed occasionally nine months later by one man.

Dyspepsia Dyspepsia occurred at some time in 16 patients. It was fairly severe in seven of them. The dyspeptic symptoms in these cases started between the fifth and ninth month of treatment; as a result, the total number of cachets taken was between 50% and 80% of the prescribed dose over the nine months. The nine cases of slight dyspepsia developed in the course usually at about three months. Six of these completed their full
treatment in spite of dyspepsia; the other three took between 50 and 85% of the prescribed dose. Six patients suffered from both vertigo and dyspepsia.

Weight rise Figure 3 shows that the average weight of the men in the two groups going to hospital rose steeply during the three months' admission, the rise being greater in the group without drugs. The mean weight rise of the rest group was 4.3 kg; in those on chemotherapy with no dyspepsia, 2.8 kg; and of the 19 men with dyspepsia from P.A.S., 2.0 kg. This weight rise (not seen in the working group) delayed some miners returning to full work at once on account of increased breathlessness, but within 18 months the effect on weight was reversed.

Fall in ventilatory capacity Figure 3 also shows the changes in ventilatory capacity. There was a sharp fall in the first three months in the two groups in hospital, but by 24 months the difference between the three groups had disappeared. These and other changes in lung function have been reported in detail elsewhere (Cotes and Gilson, 1967). It was concluded that the fall in F.E.V. was due to the weight increase and unrelated to the inactivity, the smoking habits, or the chemotherapy, except in so far as these factors affected the weight.

Employment We expected that a period in hospital might affect the pattern of employment compared with those in the working group. Table VI shows that the groups who were treated in hospital had a work record at one year very similar to that of the working group. Of the five men in the chemotherapy group who were unemployed at one year, two had persistent streptomycin vertigo. One of these later returned to light work; the other developed a disabling compensation neurosis, partly the result of vertigo. The other three were unemployed for reasons unrelated to the trial.

| TABLE VI |
| CHANGES IN EMPLOYMENT AT ONE YEAR AFTER ENTRY |
|----------|----------------|--------|--------|--------|---------|
|          | No Change | Change of Job Under-ground | Left Mining | Unemployed | Total seen at 1 year |
| Chemotherapy | Rest | Working |
| --------------|-------|---------|----------|-----------|---------------------|
| Chemotherapy   | 44    | 5       | 2        | 5         | 56                  |
| Rest           | 44    | 9       | 1        | 3         | 57                  |
| Working        | 50    | 4       | 2        | 2         | 58                  |

To summarize the disadvantages of the treatment, the persistent ill-effect was vertigo in the dark in four miners, two of whom remained unemployed for long periods. The transient ill-effects were weight gain, impaired ventilatory capacity, and dyspepsia.

CORRELATION BETWEEN PROGRESSION AND OTHER FINDINGS This trial gave an opportunity to look at correlations between radiological progression over three years and chest symptoms; smoking habits; E.S.R.; tuberculin sensitivity; and rheumatoid factor.

Chest symptoms None of the symptoms recorded on the questionnaire at the start of the trial showed any correlation with radiological progression or change in area, nor were they related to the treatment group.

Smoking Analysis of the relation of initial smoking habits divided into four groups (non-smokers; ex-smokers; light (<15 cigarettes/day); and heavy smokers (>15 cigarettes/day)) showed no association with the initial area of the shadows or the change of area over three years.

Sedimentation rate Table VII shows the initial E.S.R. (Westergren) and change in E.S.R. after two years, related to radiological progression for the two groups treated in hospital. For this pur-
**A controlled trial of anti-tuberculosis chemotherapy in pneumoconiosis of coalworkers**

**Table VII**

REST AND CHEMOTHERAPY GROUPS

<table>
<thead>
<tr>
<th>Initial E.S.R. (mm. in 1 hr)</th>
<th>Change of E.S.R. after 2 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Decrease &gt; 2 mm.</td>
</tr>
<tr>
<td>0-5</td>
<td>7</td>
</tr>
<tr>
<td>&gt;5</td>
<td>14</td>
</tr>
<tr>
<td>Total</td>
<td>21</td>
</tr>
<tr>
<td>?P</td>
<td>10</td>
</tr>
<tr>
<td>?NC</td>
<td>5</td>
</tr>
<tr>
<td>?R and R</td>
<td>2</td>
</tr>
<tr>
<td>Totals</td>
<td>31</td>
</tr>
</tbody>
</table>

Two observers' readings combined: P = ?P + ?P or P + ?P

pose the radiological readings of the two observers were combined to give a single reading. Cases with a higher initial E.S.R. were not more likely to progress. We were, therefore, not able to confirm the findings of Stewart and his colleagues (1948). A correlation between radiological progression and increase of E.S.R. during two years is present; of those whose E.S.R. increased by more than 2 mm., 68% showed progression or doubtful progression compared with 45% in those with no change or a decrease of E.S.R. (P<0.05). This finding is of no material help in identifying in advance men likely to progress.

**Mantoux tests** These were made with 1 and 10 T.U. doses (old tuberculin) and read at 72 hours by the same observer (C.E.) throughout the trial. There was no relation in those with a positive test between the diameter of the reaction and the area of the radiographic shadow or the change in area over three years; but in those with a negative test (less than 1 mm.) to 1 T.U. (32 out of 115 tested) definite progression occurred in only 3 (9.4%) compared with 21 out of 83 (25.3%) in those with a positive test. The difference is significant (P=0.046) for a one-sided test.

A histogram of the numbers showing wheals of different sizes to 10 T.U. shows a distribution very similar to that of Hart, Cochrane, and Higgins (1963), who used 5 T.U., though the mean was naturally somewhat larger, 13.9 mm. in our series compared with their mean of 10.4 mm.

**Rheumatoid factor** Aggregated human γ-globulin (AHGG) was used to detect rheumatoid factor in the serum by the method described by Pernis, Vigliani, and Selikoff (1965). This measurement was made towards the end of the trial; 157 subjects were tested and the titre at 36 months was used. Forty-two (27%) showed a titre positive above 1 in 10, 21 of these being positive at 1 in 80 or above. There was no correlation with radiological change. Those with negative titres had smaller initial shadow areas compared with those with positive titres (P<0.05), but there was no trend with height of titre. The change in area showed no relationship with titre.

Thus, in the search for indications of the likelihood that progression may occur in a patient with P.M.F., we have had little success. Symptoms and smoking habits are no guide, neither is the E.S.R. or AHGG titre. A negative Mantoux is associated with a reduced chance of progression.

**DISCUSSION**

The doubts expressed by the Medical Research Council committee on the practicability of this trial have in the event proved to be unfounded, mainly because of such ready co-operation from the miners and their Union officials and the help given by the staffs of the National Coal Board, the Ministry of Pensions and National Insurance (now Ministry of Social Security), and the Welsh Hospital Board.

The trial has shown that there are particular difficulties in measuring small changes in ill-defined radiographic shadows in complicated pneumoconiosis even over a three-year period. After using the two methods of assessing the radiographs and two observers, we concluded that one year of anti-tuberculosis chemotherapy, with as high a dose as is practicable, had no significant effect on the progression of the disease followed over three years. Although this is true of the total series, there is a little evidence to indicate that there may be a small sub-group of patients who do respond to treatment, but unfortunately if they exist we found no means of predicting them, either from a special study of the characteristics of the shadows, or the E.S.R., or other factors. Those with a negative Mantoux 1 T.U. initially are slightly but significantly less likely to progress.

The conclusion that the disease as measured by the radiographic appearance is not influenced by this treatment has practical therapeutic implications, because chemotherapy in hospital had appreciable transient and occasional long-term ill-effects. In particular, the late effects of streptomycin toxicity, which may be only a slight inconvenience to most patients, may prevent a miner continuing to work underground because it is much more disabling in poor light and when carrying loads on uneven ground. We therefore conclude that in the absence of means of predicting those who will respond—if they exist—anti-
tuberculosis chemotherapy is not justified in miners with P.M.F. who are sputum-negative for tubercle bacilli. The trial supports the conclusions of the only two previous controlled trials of this kind (Miall et al., 1954; McCallum, 1961). We considered the use of steroids and anti-
tuberculosis therapy in planning the trial but rejected the opinion on account of the risk of complications. Our views are not altered after completion of the trial.

This trial adds a little to the evidence from other sources (Cochrane, 1962; Hart et al., 1963) that tuberculosis is probably not a major factor in the pathogenesis of P.M.F. As chemotherapy did not prevent the development of new shadows, tuberculous infection probably does not initiate the new foci of P.M.F. The lack of effect of chemotherapy on the progression suggests that tuberculosis is not responsible at this later stage in a majority of cases. However, the slender evidence from this trial and the earlier one by Miall et al. (1954), that chemotherapy may benefit a small proportion of cases even though these cannot be identified ahead, could be interpreted as supporting the view that P.M.F. has more than one aetiology. The diagnosis in life is radiological; it is known that some cases diagnosed as P.M.F. have a positive sputum and respond well to therapy (M.R.C./Miners’ Treatment Centre Trials, 1963), but these cases cannot be identified for certain on radiological features alone. If P.M.F. has a multiple aetiology—silicotic in some cases, immunological in others, and tuberculous in a few—one might expect to find a case developing a positive sputum even though previously sputum negative. This occurred in one instance in this trial.

The negative results do not exclude the possibility that a mycobacterial infection resistant to the drugs used may also play a part in the pathogenesis of complicated pneumoconiosis. There is evidence of an association between coalworkers’ pneumoconiosis and drug-resistant anonymous mycobacterial infection (Kamat, Rossiter, and Gilson, 1961), and three cases of intermittent positive sputum with M. peregrinum (Runyon group IV) were observed in the trial, but their course over three years did not differ obviously from the rest.

The excellent co-operation of the miners of South Wales and their Union representatives made this trial possible. We are deeply grateful for their support and understanding. We acknowledge the help at every stage of Dr. J. Rogan, Chief Medical Officer of the National Coal Board, and the Area Medical Officers of the N.C.B., on whose initial interviews with the miners much depended. We had excellent support from the medical and administrative staff of the Pneumoconiosis Panels of the Ministry of Pensions and National Insurance. The Welsh Hospital Board made a special ward available at Talgarth Sanatorium, and the trial would have been impossible without the help of the staff there, including the late Dr. H. A. Ross, and Dr. Ivor Williams, Dr. J. Coutts, and Dr. W. Ganciwicz.

We wish to acknowledge the help of our colleagues at the Pneumoconiosis Research Unit, especially Mr. W. H. Roberts, and at the Miners’ Chest Diseases Treatment Centre, especially Mrs. F. E. Willson.

We are especially grateful to Professor J. Crofton, Professor A. L. Cochrane, Dr. I. T. T. Higgins, and Dr. W. E. Miall for their contribution to the planning and initial stages of the trial, and to Dr. J. Marks for the bacteriology of the sputum.

REFERENCES


Marks, J. (1968). (Paper in preparation.)

Medical Research Council Committee on the Aetiology of Chronic Bronchitis (1965). Definition and classification of chronic bronchitis. Lancet, 1, 775.


A controlled trial of anti-tuberculosis chemotherapy in the early complicated pneumoconiosis of coalworkers

J. D. Ball, G. Berry, W. G. Clarke, J. C. Gilson, J. Thomas, Catherine Exall and Marjorie Roberts

*Thorax* 1969 24: 399-406
doi: 10.1136/thx.24.4.399

Updated information and services can be found at:
http://thorax.bmj.com/content/24/4/399

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/